欧州の精密医療市場：エコシステムと国別 - 分析と予測（2024年～2034年）

欧州の精密医療の市場規模は、2024年の407億5,000万米ドルから2034年には1,187億9,000万米ドルに達すると予測され、2024年から2034年の予測期間中のCAGRは11.29%と見込まれています。

ゲノム、診断、標的薬の進歩が欧州の精密医療分野を牽引しています。主な要因としては、慢性疾患の蔓延、デジタルヘルスリソースの統合、個別化ヘルスケアの重視の高まりなどが挙げられます。カスタマイズされた医薬品の創出は、政府プログラムや研究提携によって支援されており、患者の調査結果を増大させています。さらに、バイオマーカー、次世代シーケンシング、AIを活用した診断の広範な利用により、珍しい病気、心臓病、腫瘍学のケアも変化しています。この地域の強固なヘルスケア・インフラと個別化治療に対する意識の高まりにより、精密医療はさまざまな医療現場で急速に導入されつつあります。

画一的な治療法から高度にカスタマイズされた治療法まで、欧州の精密医療市場はヘルスケア環境を劇的に変化させています。特にゲノミクス、次世代シーケンシング、バイオマーカー同定の分野における技術の進歩により、より専門的な病気の診断・治療方法が可能になっています。個別化治療は、まれな遺伝性疾患、心血管疾患、腫瘍学において、患者の転帰を大きく改善しつつあります。有用な政策を推進し、研究開発に多額の投資を行うことで、欧州各国政府はこの変化に貢献してきました。患者のプライバシーとデータの安全性に関する厳格なガイドラインを維持する一方で、規制機関は精密治療の承認手続きを迅速化しています。

この市場は、製薬会社、バイオテクノロジー企業、学術機関の戦略的提携によってさらに強化され、イノベーションと共同研究のエコシステムが醸成されています。デジタルヘルスツールや人工知能が臨床ワークフローにますます統合され、診断精度と治療のカスタマイズが強化されています。先端技術の高コスト、規制の複雑さ、強固なヘルスケアインフラの必要性といった課題にもかかわらず、精密医療の勢いは依然として強いです。欧州は、公的資金と民間投資に支えられた個別化医療への取り組みにより、臨床診療を再定義し、患者中心の医療を提供する世界的リーダーとしての地位を確立しています。

遺伝学、人工知能、個別化治療の選択肢を可能にする医療技術の進歩が、欧州における精密医療ビジネスの急速な進化を促しています。特に腫瘍学や珍しい疾患では、次世代シーケンシングとバイオマーカー開発の組み合わせが早期発見と集中治療を促進しています。市場は、政府プログラム、ヘルスケアイノベーションへの融資拡大、共同研究活動により拡大しています。人口の高齢化、慢性疾患の有病率の増加、より効率的な治療計画の必要性により、市場は拡大しています。しかし、普及の障害となっているのは、高額なコスト、複雑な法的枠組み、データ・プライバシーの問題などです。従来のヘルスケアシステムに精密医療を取り入れるには、大規模なインフラ投資と患者教育が必要です。このような障害にもかかわらず、技術開発とバイオテクノロジー、製薬、学術機関の戦略的提携により、よりまとまりのある効果的な精密医療エコシステムへの扉が開かれつつあります。

製品/イノベーション戦略：当レポートは、精密医療における最新の技術的進歩に関する深い洞察を提供し、企業がイノベーションを推進し、市場のニーズに合わせた最先端の製品を開発することを可能にします。

成長/マーケティング戦略：包括的な市場分析を提供し、主要な成長機会を特定することで、ターゲットとなるマーケティング戦略を策定し、市場でのプレゼンスを効果的に拡大するための知識を組織に提供します。

競合戦略：競合情勢の徹底的な分析により、競合企業の強みと弱みを理解し、市場における競争優位性を獲得するための効果的な戦略立案を支援します。

当レポートでは、欧州の精密医療市場について調査し、市場の概要とともに、エコシステムと国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場概要

• 市場定義
• 精密医療：患者中心医療の創生における最前線
• 精密医療：画一的な治療法を個人に合わせた治療法に再構築
• イニシアチブとプログラム
• 精密医療：実現技術と応用

第2章 市場：業界展望

• 精密医療市場：エコシステム分析
• 市場動向
• 業界考察
• エコシステムのサマリー

第3章 地域

• 概要
• 欧州
  • 地域概要
  • 市場成長促進要因
  • 市場成長抑制要因
  • ドイツ
  • フランス
  • イタリア
  • 英国
  • スペイン
  • その他

第4章 競合情勢

• 競合情勢
• 企業プロファイル
  • Almac Group
  • ANGLE plc
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • QIAGEN N.V.
  • bioMerieux SA
  • Sanofi S.A.
  • Randox Laboratories Ltd.
  • GSK plc
  • Novartis AG
  • Menarini Silicon Biosystems

第5章 調査手法

List of Figures

• Figure 1: Europe Precision Medicine Market, $Billion, 2023, 2028, and 2034
• Figure 2: Precision Medicine: Treatment Tailored to an Individual's Genetic Structure
• Figure 3: Precision Medicine - a Multi-Faceted Approach to Patient Care
• Figure 4: Decreasing Cost ($) and Increasing Output (TB) of Genome Sequencing, 2009-2025
• Figure 5: Precision Medicine Market (by Region), $Billion, 2023, 2028, and 2034
• Figure 6: Europe Precision Medicine Market (by Ecosystem), $Billion, 2023, 2028, and 2034
• Figure 7: Precision Medicine Approach
• Figure 8: Evolution of Precision Medicine Technology
• Figure 9: Precision Medicine: Enabling Technologies and Applications
• Figure 10: Structured Big Data Reporting Benefits
• Figure 11: Generalized Process for the Microarray
• Figure 12: Stakeholders in Precision Medicine
• Figure 13: Number of Patents Files, 2020-2024
• Figure 14: Precision Medicine by Top Patent Owner
• Figure 15: Europe Precision Medicine Market, $Billion, 2023-2034
• Figure 16: Germany Precision Medicine Market, $Billion, 2023-2034
• Figure 17: France Precision Medicine Market, $Billion, 2023-2034
• Figure 18: Italy Precision Medicine Market, $Billion, 2023-2034
• Figure 19: U.K. Precision Medicine Market, $Billion, 2023-2034
• Figure 20: Spain Precision Medicine Market, $Billion, 2023-2034
• Figure 21: Rest of Europe Precision Medicine Market, $Billion, 2023-2034
• Figure 22: Synergistic Activities, by Company (January 2020- January 2025)
• Figure 23: Synergistic Activities, by Type (January 2020- January 2025)
• Figure 24: Data Triangulation
• Figure 25: Top-Down and Bottom-Up Approach

List of Tables

• Table 1: Market Snapshot
• Table 2: Application
• Table 3: Pipeline Analysis (by Company)
• Table 4: Pipeline Analysis (by Product)
• Table 5: Precision Medicine Drugs Pipeline Analysis
• Table 6: Ecosystem Summary
• Table 7: Precision Medicine Market (by Region), $Million, 2023-2034
• Table 8: Europe Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 9: Germany Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 10: France Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 11: Italy Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 12: Funding Scenario in Universities
• Table 13: U.K. Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 14: Spain. Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 15: Rest-of-Europe Precision Medicine Market (by Ecosystem), $Billion, 2023-2034

Introduction to Europe Precision Medicine Market

The Europe precision medicine market is projected to reach $118.79 billion by 2034 from $40.75 billion in 2024, at a CAGR of 11.29% during the forecast period of 2024-2034. Advances in genomes, diagnostics, and targeted medicines are driving the precision medicine sector in Europe. Key factors include the growing prevalence of chronic diseases, the integration of digital health resources, and an increased emphasis on personalised healthcare. The creation of customised medicines is being aided by government programs and research partnerships, which is increasing patient results. Furthermore, the care of uncommon illnesses, cardiology, and oncology is changing due to the extensive use of biomarkers, next-generation sequencing, and AI-powered diagnostics. Precision medicine is being adopted more quickly in a variety of healthcare settings thanks to the region's robust healthcare infrastructure and rising awareness of personalised treatment.

Market Introduction

From one-size-fits-all therapies to highly customised therapeutic options, the precision medicine market in Europe is drastically changing the healthcare environment. More specialised methods of diagnosing and treating diseases have been made possible by technological advancements, especially in the fields of genomics, next-generation sequencing, and biomarker identification. Personalised therapies are greatly improving patient outcomes in uncommon genetic disorders, cardiovascular diseases, and oncology. By promoting policies that are helpful and making significant investments in research and development, European governments have been instrumental in this change. While maintaining strict guidelines for patient privacy and data security, regulatory bodies are expediting the approval procedures for precision treatments.

The market is further bolstered by strategic alliances among pharmaceutical companies, biotech firms, and academic institutions, fostering an ecosystem of innovation and collaborative research. Digital health tools and artificial intelligence are increasingly integrated into clinical workflows, enhancing diagnostic accuracy and treatment customization. Despite challenges such as the high cost of advanced technologies, regulatory complexities, and the need for robust healthcare infrastructure, the momentum behind precision medicine remains strong. Europe's commitment to personalized healthcare, underpinned by public funding and private investment, positions the region as a global leader in redefining clinical practices and delivering patient-centric care.

Market Segmentation

Segmentation 1: by Ecosystem

• Applied Science
• Precision Diagnostics
• Digital Health and Information Technology
• Precision Therapeutics

Segmentation 2: by Region

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

Market Trends, Drivers and Challenges of Europe Precision Medicine Market

Advances in genetics, artificial intelligence, and health technology that allow for individualised treatment options are driving a rapid evolution of the precision medicine business in Europe. Especially in oncology and uncommon disorders, the combination of next-generation sequencing and biomarker development is promoting early detection and focused treatments. The market is expanding thanks to government programs, more financing for healthcare innovation, and cooperative research activities. The market is expanding due to ageing populations, an increase in the prevalence of chronic diseases, and a need for more efficient treatment plans. However, obstacles to wider adoption include expensive costs, intricate legal frameworks, and data privacy issues. It takes large infrastructure investments and patient education to incorporate precision medicine into traditional healthcare systems. Notwithstanding these obstacles, technological developments and strategic alliances between biotech, pharmaceutical, and academic organisations are opening the door to a more cohesive and effective precision medicine ecosystem, which will eventually lead to better patient outcomes and a shift in Europe towards individualised healthcare solutions.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in precision medicine, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Almac Group Ltd.
• ANGLE plc
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• QIAGEN N.V.

Table of Contents

1 Market Overview

• 1.1 Market Definition
• 1.2 Precision Medicine: A Frontier in the Genesis of Patient-Centric Medicine
• 1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
• 1.4 Initiatives and Programs
• 1.5 Precision Medicine: Enabling Technologies and Applications
  • 1.5.1 Innovators
    • 1.5.1.1 3D DNA Printing
      • 1.5.1.1.1 Introduction
      • 1.5.1.1.2 Role of 3D DNA Printing
    • 1.5.1.2 RNA-Seq
      • 1.5.1.2.1 Introduction
      • 1.5.1.2.2 Role of RNA-Seq in Precision Medicine
      • 1.5.1.2.3 Key Players
    • 1.5.1.3 4D Molecular Imaging
      • 1.5.1.3.1 Introduction
      • 1.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
      • 1.5.1.3.3 Key Players
  • 1.5.2 Early Adopters
    • 1.5.2.1 CRISPR
      • 1.5.2.1.1 Introduction
      • 1.5.2.1.2 Role of CRISPR in Precision Medicine
      • 1.5.2.1.3 Key Players
    • 1.5.2.2 Blockchain
      • 1.5.2.2.1 Introduction
      • 1.5.2.2.2 Role of Blockchain in Precision Medicine
      • 1.5.2.2.3 Key Players
    • 1.5.2.3 Imaging Informatics
      • 1.5.2.3.1 Introduction
      • 1.5.2.3.2 Role of Imaging Informatics in Precision Medicine
      • 1.5.2.3.3 Key Players
  • 1.5.3 Early Majority
    • 1.5.3.1 Artificial Intelligence (AI)
      • 1.5.3.1.1 Introduction
      • 1.5.3.1.2 Role of Artificial Intelligence in Precision Medicine
      • 1.5.3.1.3 Key Players
    • 1.5.3.2 Circulating Free DNA (cfDNA)
      • 1.5.3.2.1 Introduction
      • 1.5.3.2.2 Role of cfDNA in Precision Medicine
      • 1.5.3.2.3 Key Players
    • 1.5.3.3 Big Data
      • 1.5.3.3.1 Introduction
      • 1.5.3.3.2 Role of Big Data in Precision Medicine
      • 1.5.3.3.3 Key Players
    • 1.5.3.4 Next-Generation Sequencing (NGS)
      • 1.5.3.4.1 Introduction
      • 1.5.3.4.2 Role of NGS in Precision Medicine
      • 1.5.3.4.3 Key Players
    • 1.5.3.5 Health Informatics
      • 1.5.3.5.1 Introduction
      • 1.5.3.5.2 Role of Health Informatics in Precision Medicine
      • 1.5.3.5.3 Key players
    • 1.5.3.6 Bioinformatics
      • 1.5.3.6.1 Introduction
      • 1.5.3.6.2 Role of Bioinformatics in Precision Medicine
      • 1.5.3.6.3 Key Players
  • 1.5.4 Late Majority
    • 1.5.4.1 Polymerase Chain Reactions (PCR)
      • 1.5.4.1.1 Introduction
      • 1.5.4.1.2 Role of PCR in Precision Medicine
      • 1.5.4.1.3 Key players
    • 1.5.4.2 Microarray
      • 1.5.4.2.1 Role of Microarray in Precision Medicine
      • 1.5.4.2.2 Key Players

2 Market: Industry Outlook

• 2.1 Precision Medicine Market: Ecosystem Analysis
• 2.2 Market Trends
  • 2.2.1 Integrating Advanced Imaging for Enhanced Diagnostics and Treatment
  • 2.2.2 Emergence of Biobanks as a Cornerstone of Precision Medicine
• 2.3 Industry Insights
  • 2.3.1 Patent Analysis
  • 2.3.2 Pipeline Analysis
  • 2.3.3 Legal Requirements and Framework by the EMA
• 2.4 Ecosystem Summary

3 Region

• 3.1 Overview
• 3.2 Europe
  • 3.2.1 Regional Overview
  • 3.2.2 Driving Factors for Market Growth
  • 3.2.3 Factors Challenging the Market
    • 3.2.3.1 Europe Precision Medicine Market (by Ecosystem),
  • 3.2.4 Germany
    • 3.2.4.1 Germany Precision Medicine Market (by Ecosystem),
  • 3.2.5 France
    • 3.2.5.1 France Precision Medicine Market (by Ecosystem)
  • 3.2.6 Italy
    • 3.2.6.1 Italy Precision Medicine Market (by Ecosystem),
  • 3.2.7 U.K.
    • 3.2.7.1 U.K. Precision Medicine Market (by Ecosystem),
  • 3.2.8 Spain
    • 3.2.8.1 Spain. Precision Medicine Market (by Ecosystem),
  • 3.2.9 Rest-of-Europe
    • 3.2.9.1 Rest-of-Europe Precision Medicine Market (by Ecosystem)

4 Competitive Landscape

• 4.1 Competitive Landscape
  • 4.1.1 Synergistic Activities
• 4.2 Company Profiles
  • 4.2.1 Almac Group
    • 4.2.1.1 Overview
    • 4.2.1.2 Top Products/Services
    • 4.2.1.3 Top Competitors
    • 4.2.1.4 Analyst View
  • 4.2.2 ANGLE plc
    • 4.2.2.1 Overview
    • 4.2.2.2 Top Products
    • 4.2.2.3 Top Competitors
    • 4.2.2.4 Analyst View
  • 4.2.3 F. Hoffmann-La Roche Ltd.
    • 4.2.3.1 Overview
    • 4.2.3.2 Top Products
    • 4.2.3.3 Top Competitors
    • 4.2.3.4 Analyst View
  • 4.2.4 Merck KGaA
    • 4.2.4.1 Overview
    • 4.2.4.2 Top Products
    • 4.2.4.3 Top Competitors
    • 4.2.4.4 Analyst View
  • 4.2.5 QIAGEN N.V.
    • 4.2.5.1 Overview
    • 4.2.5.2 Top Products
    • 4.2.5.3 Top Competitors
    • 4.2.5.4 Analyst View
  • 4.2.6 bioMerieux SA
    • 4.2.6.1 Overview
    • 4.2.6.2 Top Products
    • 4.2.6.3 Top Competitors
    • 4.2.6.4 Analyst View
  • 4.2.7 Sanofi S.A.
    • 4.2.7.1 Overview
    • 4.2.7.2 Top Products
    • 4.2.7.3 Top Competitors
    • 4.2.7.4 Analyst View
  • 4.2.8 Randox Laboratories Ltd.
    • 4.2.8.1 Overview
    • 4.2.8.2 Top Products
    • 4.2.8.3 Top Competitors
    • 4.2.8.4 Analyst View
  • 4.2.9 GSK plc
    • 4.2.9.1 Overview
    • 4.2.9.2 Top Products
    • 4.2.9.3 Top Competitors
    • 4.2.9.4 Analyst View
  • 4.2.10 Novartis AG
    • 4.2.10.1 Overview
    • 4.2.10.2 Top Products
    • 4.2.10.3 Top Competitors
    • 4.2.10.4 Analyst View
  • 4.2.11 Menarini Silicon Biosystems
    • 4.2.11.1 Overview
    • 4.2.11.2 Top Products
    • 4.2.11.3 Top Competitors
    • 4.2.11.4 Analyst View

5 Research Methodology

• 5.1 Precision Medicine Market: Research Methodology
  • 5.1.1 Data Sources
    • 5.1.1.1 Primary Data Sources
    • 5.1.1.2 Secondary Data Sources
  • 5.1.2 Data Triangulation
• 5.2 Market Estimation and Forecast